Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.91 | N/A | +29.07% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.91 | N/A | +29.07% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution about current market conditions. They are focused on adapting strategies to navigate these challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
The earnings report indicates that Twist Bioscience is facing challenges, as reflected in their negative EPS. The stock's decline of 2.32% suggests that investors are reacting to the cautious tone from management and the lack of revenue figures. Without guidance, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TENCENT MUSIC ENTMT A ADR
Nov 15, 2022